Integrity(®) bare-metal coronary stent-induced platelet and endothelial cell activation results in a higher risk of restenosis compared to Xience(®) everolimus-eluting stents in stable angina patients

Platelets
Tibor SzükBéla Nagy Jr

Abstract

Drug-eluting stenting (DES) has become a reliable tool for coronary stenting; however, its direct effects on platelet and endothelium function differ from those of bare-metal stenting (BMS). This study involved a periprocedural analysis of various biomarkers of cellular activation after elective DES (Xience(®), Abbott Vascular, Santa Clara, CA, USA) or BMS (Integrity(®), Medtronic, Minneapolis, MI, USA). Forty-nine stable angina patients were recruited: 28 underwent BMS, and 21 received everolimus-eluting stents. Samples were collected (i) prior to stenting, (ii) at 24 hours after procedure, and (iii) after 1 month of dual antiplatelet therapy. Platelet activation was analyzed by surface P-selectin positivity in parallel with plasma levels of soluble P-selectin, CD40L and platelet-derived growth factor (PDGF). Endothelial cell (EC) activation was detected by measuring markers of early (von Willebrand factor) and delayed response (VCAM-1, ICAM-1, E-selectin). Patients were followed for 6 months for the occurrence of restenosis or stent thrombosis. Increased platelet activation was sustained regardless of stent type or antiplatelet medication. Concentrations of most EC markers were more elevated after BMS than after DES. No stent...Continue Reading

References

Oct 3, 2003·The New England Journal of Medicine·Jeffrey W MosesUNKNOWN SIRIUS Investigators
Jun 3, 2004·European Heart Journal·Antonio Colombo, Ioannis Iakovou
Jan 31, 2007·The American Journal of Cardiology·Robert J ApplegateWilliam C Little
May 24, 2008·Journal of the American College of Cardiology·Peter W GroeneveldFeifei Yang
May 26, 2009·JACC. Cardiovascular Interventions·Brian HorstAmir Lerman
Jan 1, 2008·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Steve RamcharitarPatrick W Serruys
Apr 8, 2010·Journal of Thrombosis and Thrombolysis·Peter S MunkAlf I Larsen
Apr 24, 2010·Seminars in Thrombosis and Hemostasis·Rory R Koenen, Christian Weber
Oct 13, 2010·Expert Review of Cardiovascular Therapy·Bimmer E ClaessenJan J Piek
Dec 7, 2010·The American Journal of Cardiology·Francesco De FeliceRoberto Violini
Feb 18, 2011·Circulation. Cardiovascular Interventions·Steven O MarxAndrew R Marks
Jul 12, 2011·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Alexander SheehyIgor Polyakov
Nov 23, 2011·Anesthesia and Analgesia·Alisa S WolbergKellie R Machlus
Apr 25, 2012·Archives of Internal Medicine·Giuseppe De LucaUNKNOWN Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation

❮ Previous
Next ❯

Citations

Nov 30, 2020·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Béla NagyMiklós Fagyas
Oct 30, 2021·Clinical Chemistry and Laboratory Medicine : CCLM·Fabio AngeliClaudio Cavallini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

JACC. Cardiovascular Interventions
Neville KukrejaInterventional Cardiologists of the Thoraxcenter (2000 to 2005)
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
Inder M SinghMehdi H Shishehbor
© 2022 Meta ULC. All rights reserved